MedTrace Logo

PENG: an Estimation of ED50 in Neck of Femur Fracture

NCT05095025 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2021-10-27

No results posted yet for this study

Summary

The effective dose of local anaesthetic used in PENG blocks to achieve analgesia in patients with fractured neck of femur is unknown. It is planned to address this question using a dixon/massey sequential dosing methodology to establish the ED50 of 0.25% Bupivacaine.

Conditions

  • Hip Fractures
  • Pain, Acute

Interventions

DRUG

Bupivacaine Hydrochloride 20ml injectate

Sequential dosing, starting at 50mg with 5mg increments based on the outcome of the preceding participant

Sponsors & Collaborators

  • University College Cork

    lead OTHER

Principal Investigators

  • Brian O'Donnell, MD · UCC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-14
Primary Completion
2022-09-01
Completion
2022-10-01

Countries

  • Ireland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05095025 on ClinicalTrials.gov